Background It has reported that Iguratimod (IGU), one of methanesulfonanilide of anti-inflamamatory agents, can inhibit anti-arthritic activity of rheumatoid arthritis (RA). IGU was approved for rheumatoid arthritis patients with inappropriate response to conventional treatments in Japan in September 2012.
Objectives We aimed to assess the efficacy of IGU alone or in combination with Methotrxate (MTX) in patients with rheumatoid Arthritis
Methods Patients who had an inadequqte response to MTX were enrolled. From December 2012, forty nine patients treated with IGU were analyzes retrospectively; 17 of 49 patients were treated with only IGU, 32 of 49 patients were treated with add-on IGU in combination with MTX. Disease activity and clinical response were assessed by disease activity score 28/ESR (DAS28-ESR) and EULAR response criteria, respectively. The DAS28-ESR, CRP, SDAI, CDAI at 1, 2, 3, 6, 12, 24 months from administration of IGU were examined.
Results The average amount of IGU is 40.7mg in MTX group and 41.3mg in non- MTX group. The average amount of MTX was 7mg. After follow up 24 months, escape cases was six cases. The DAS28-ESR. After 12 months of treatment, The DAS28-ESR was decreased from4.32 to 2.37 significantly in MTX group (P<0.01), and also decreased from4.23 to 2.37 significantly in non-MTX group (P<0.01). According to EULAR response criteria at 12 months, The DAS28-ESR remission was observed in 46.9% of patients in MTX group and 52.9% in non- MTX group. CRP decreased from1.9 to 0.7 significantly in MTX group (P<0.01), and also decreased from 2.1 to 0.8 significantly in non-MTX group (P<0.05).There was no significant difference between the two groups.
Conclusions Based on these results, we can conclude that the treatment of IGU is effective and well tolerated, and represents a new option for RA patients, including patient with inadequqte response to MTX.
Liang-jing Lu,et al. Multicenter,dandomized,double-blind,controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis. Rheumatol 61, No. 7 July 2009:979–987
Y Aikawa, et al.An anti-rheumatic agent T-614 inhibits NF-kB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IkBα degration. Inflammation Research April 2002,Vol51 4:188–194
Xu Y, et al Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid.Medators Inflamm 2015 Dec 2.:1155
Okamura K, et al. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol2015 Mar;25(2):235–40
Disclosure of Interest None declared